N. Rezaei, S. Khanmohammadi, S. Zoghi, Elham Rayzan, S. Shahkarami, R. Jimenez Heredia, A. Frohne, Simin Seyedpour, K. Boztug
{"title":"A Rare PTPN11 Mutation in a Patient with Juvenile Myelomonocytic\nLeukemia: A Case Report","authors":"N. Rezaei, S. Khanmohammadi, S. Zoghi, Elham Rayzan, S. Shahkarami, R. Jimenez Heredia, A. Frohne, Simin Seyedpour, K. Boztug","doi":"10.2174/1875692120666221124113404","DOIUrl":null,"url":null,"abstract":"\n\nJuvenile myelomonocytic leukemia (JMML) is a rare childhood disease characterized by hepatosplenomegaly, monocytosis, anemia, increased white blood cell\ncount, thrombocytopenia, skin infiltration, and elevated fetal hemoglobin. Mutation in specific\ngenes, including KRAS, NRAS, PTPN11, and NF1, can lead to the development of JMML.\n\n\n\nA two-year-old boy with a history of inguinal abscess at the age of 12\nmonths and surgery due to infectious lymphadenitis was referred to the hospital. His parents\nalso reported a history of oral candidiasis, recurrent otitis media, and lymphadenopathy in\nthe patient. The physical examination showed splenomegaly, macular rash, lymphadenopathy in the neck region, and rashes in the inguinal region and on the hands and feet. Laboratory and flow cytometry data showed lymphocytosis, low hemoglobin, thrombocytopenia,\nmonocytosis, eosinophilia, and a shift to the left in the peripheral blood. The bone marrow\naspiration showed a cellular marrow with myeloid hyperplasia. Whole-exome sequencing\nrevealed a rare heterozygous ENST00000351677.2:c.1508G>C, p.Gly503Ala variant in\nPTPN11. The patient was diagnosed with JMML but, unfortunately, passed away.\n\n\n\nWe report a rare heterozygous mutation in the PTPN11 gene in a two-year-old\nboy diagnosed with JMML. This uncommon mutation should be considered in the mutational screening protocol of JMML. Management of JMML with RAS pathway targeted\ntherapy may also have promising results and needs further investigations.\n","PeriodicalId":11056,"journal":{"name":"Current Pharmacogenomics and Personalized Medicine","volume":"8 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Pharmacogenomics and Personalized Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1875692120666221124113404","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0
Abstract
Juvenile myelomonocytic leukemia (JMML) is a rare childhood disease characterized by hepatosplenomegaly, monocytosis, anemia, increased white blood cell
count, thrombocytopenia, skin infiltration, and elevated fetal hemoglobin. Mutation in specific
genes, including KRAS, NRAS, PTPN11, and NF1, can lead to the development of JMML.
A two-year-old boy with a history of inguinal abscess at the age of 12
months and surgery due to infectious lymphadenitis was referred to the hospital. His parents
also reported a history of oral candidiasis, recurrent otitis media, and lymphadenopathy in
the patient. The physical examination showed splenomegaly, macular rash, lymphadenopathy in the neck region, and rashes in the inguinal region and on the hands and feet. Laboratory and flow cytometry data showed lymphocytosis, low hemoglobin, thrombocytopenia,
monocytosis, eosinophilia, and a shift to the left in the peripheral blood. The bone marrow
aspiration showed a cellular marrow with myeloid hyperplasia. Whole-exome sequencing
revealed a rare heterozygous ENST00000351677.2:c.1508G>C, p.Gly503Ala variant in
PTPN11. The patient was diagnosed with JMML but, unfortunately, passed away.
We report a rare heterozygous mutation in the PTPN11 gene in a two-year-old
boy diagnosed with JMML. This uncommon mutation should be considered in the mutational screening protocol of JMML. Management of JMML with RAS pathway targeted
therapy may also have promising results and needs further investigations.
期刊介绍:
Current Pharmacogenomics and Personalized Medicine (Formerly ‘Current Pharmacogenomics’) Current Pharmacogenomics and Personalized Medicine (CPPM) is an international peer reviewed biomedical journal that publishes expert reviews, and state of the art analyses on all aspects of pharmacogenomics and personalized medicine under a single cover. The CPPM addresses the complex transdisciplinary challenges and promises emerging from the fusion of knowledge domains in therapeutics and diagnostics (i.e., theragnostics). The journal bears in mind the increasingly globalized nature of health research and services.